CSTL Castle Biosciences, Inc.

NASDAQ
$29.62

Castle Biosciences, Inc. (CSTL) is expected to report earnings on October 29, 2026, after the market close. The consensus earnings estimate is a loss of $0.38 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.0% since its last earnings release on July 30, 2026.

Castle Biosciences Beat Consensus Estimates, Raises Guidance
Thursday, July 30, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 29
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.38)
Rev est $91.5M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $30.16

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Castle Biosciences, Inc.

Castle Biosciences is a commercial-stage dermatologic diagnostics company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions.

Sector

Healthcare

Industry

Medical Labs & Research